Roman P. Soler, MD

Medical Oncologist

Conditions Treated

Laryngeal Cancer Lung Cancer Ovarian Cancer Pleural Mesothelioma Testicular Mesothelioma

Bio & Insurance Information

Dr. Soler started his medical career in his native town Barcelona, graduating from the Universidad Autonoma medical school in 1977. Dr. Roman Soler also completed residency at the same university. For his fellowship Dr. Roman Soler moved to the United States to attend the courses of the University MD Anderson Cancer Center. Currently acting as the chairman of the department of oncology at the Montefiore Medical Center, Dr. Soler specializes and focuses on the treatment of mesothelioma. With a vast career, spanning two continents, Dr. Roman Soler received several awards and had many articles and works published, mainly regarding treatment methods for mesothelioma.


Education & Training

Universidad Autonoma - 1977

Medical School

Universidad Autonoma

Residency

University MD Anderson Cancer Center

Fellowship

Board Certifications

American Board of Internal Medicine

American Board of Internal Medicine - Oncology

Hospitals & Clinics

Burke Rehabilitation Hospital

Languages: English/Spanish

(914) 597-2500

785 Mamaroneck Ave

White Plains, New York 10605

Read More

Montefiore Medical Center

Languages: English/Spanish

(718) 405-8505

1695 Eastchester Rd

Bronx, New York 10461

Read More

SBH Health System

Languages: English/Spanish

(718) 960-9000

4422 Third Ave

Bronx, New York 10457

Read More

Publications

Dr. Roman P. Soler has contributed to 3 publications.

Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib

Ling YH1, Li T, Perez-Soler R, Haigentz M Jr.

See more >>

Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK

Yi-He Ling, Ruoping Lin, Roman Perez-Soler, Mol. Pharmacol., 74 (2008)

See more >>

Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR:p-AKT ratio predicts erlotinib sensitivity in human non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR gene

Li T1, Ling YH, Perez-Soler R.

See more >>